You are here

Article Text

Article menu
Download PDFPDF
Letter
Strong BCL10 nuclear expression identifies gastric MALT lymphomas that do not respond to H pylori eradication
  1. H Ye1,
  2. L Gong1,
  3. H Liu1,
  4. A Ruskone-Fourmestraux2,
  5. D de Jong3,
  6. S Pileri4,
  7. C Thiede5,
  8. A Lavergne6,
  9. H Boot7,
  10. G Caletti8,
  11. T Wündisch9,
  12. T Molina10,
  13. B G Taal11,
  14. S Elena12,
  15. A Neubauer13,
  16. K A MacLennan14,
  17. R Siebert15,
  18. E D Remstein16,
  19. A Dogan16,
  20. M-Q Du17
  1. 1Department of Pathology, Division of Molecular Histopathology, University of Cambridge, UK
  2. 2Service de Gastro-Enterologie, AP-HP, Hôpital St Antoine/Service d’ Anatomie Pathologique, Hotel-Dieu, Paris, France, and GELD (Groupe d’Etude des Lymphomes Digestifs), AP-HP, Fondation Francaise, de Cancérologie Digestive, France
  3. 3Department of Pathology/Gastroenterology, the Netherlands Cancer Institute, Amsterdam, the Netherlands
  4. 4Unità Operativa di Emolinfopatologia, Università degli Studi di Bologna, Italy
  5. 5Labor Molekulare Diagnostik, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
  6. 6GELD (Groupe d’Etude des Lymphomes Digestifs), AP-HP, Fondation Francaise, de Cancérologie Digestive, France, and Service Central d’Anatomie et Cytologie Pathologiques, Hopital Lariboisiere, Paris, France
  7. 7Department of Pathology/Gastroentorology, the Netherlands Cancer Institute, Amsterdam, the Netherlands
  8. 8Servizio di Gastroenterologia, Ospedale di Castel S Pietro, Castel S Pietro, Italy
  9. 9Department of Haematology, Oncology and Immunology, Philipps University Marburg, Marburg, Germany
  10. 10Service de Gastro-Enterologie, AP-HP, Hôpital St Antoine/Service d’ Anatomie Pathologique, Hotel-Dieu, Paris, France, and GELD (Groupe d’Etude des Lymphomes Digestifs), AP-HP, Fondation Francaise, de Cancérologie Digestive, France
  11. 11Department of Pathology/Gastroenterology, the Netherlands Cancer Institute, Amsterdam, the Netherlands
  12. 12Unità Operativa di Emolinfopatologia, Università degli Studi di Bologna, Italy
  13. 13Department of Haematology, Oncology and Immunology, Philipps University Marburg, Marburg, Germany
  14. 14Molecular Medicine Unit, University of Leeds, St James’s University Hospital, Leeds, U. K
  15. 15Institute of Human Genetics, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany
  16. 16Divisions of Anatomic Pathology and Hematopathology, Mayo Clinic, Rochester, USA
  17. 17Department of Pathology, Division of Molecular Histopathology, University of Cambridge, UK
  1. Correspondence to:
    Professor M-Q Du
    Department of Pathology, Division of Molecular Histopathology, University of Cambridge, Level 3, The Addenbrooke’s Hospital, Box 231, Hills Rd, Cambridge CB2 2QQ, UK; mqd20{at}cam.ac.uk

https://doi.org/10.1136/gut.2005.081117

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Approximately 75% of gastric mucosa associated lymphoid tissue (MALT) lymphomas can be cured by Helicobacter pylori eradication.1 It would be very useful to identify, at the time of diagnosis, the 25% of cases of gastric MALT lymphoma that will not respond to H pylori eradication. In general, lymphomas at stage IIE or above do not respond to H pylori eradication.2–4 However, the prognostic value of staging in stage IE cases is very limited, although tumours that involve the muscularis propria or serosa (stage IE2) show a higher failure rate than those restricted to the mucosa and submucosa (stage IE1).2–4 Paradoxically, the majority of gastric MALT lymphomas at diagnosis are at stage IE but 20% of these cases will not respond to H pylori eradication.

    In a previous study, we have examined the value of t(11;18)(q21;q21) in prediction of the response …

    View Full Text

    Footnotes

    • Conflict of interest: None declared.